Scleromyxedema: Successful treatment with IVIg and lenalidomide

Jyotsna Oak, Sandeep Goyale, Rupali Mathur, Vishal Haripara
DOI: 10.15305/ijrci/v6i1/242


Scleromyxedema is a rare progressive disorder associated with severe morbidity due to altered coarse facial features. The disease etiology is unknown. Various therapies have been investigated like the use of corticosteroids, IVIg (intravenous immunoglobulin), plasmapheresis, and thalidomide. The disorder being rare, evidence from controlled therapeutic trials is very limited. This report describes the case of a 37-year-old male with progressive scleromyxedema, without gammopathy. The patient was treated with prednisolone followed by IVIg. He showed remarkable improvement initially. Subsequent treatment with lenalidomide for one year showed complete resolution of the skin lesions with no side effects of the therapy.


1. Brown Falco O, Burgdor WHC, Wolff HH, Landthaaler M Lublin:Czelej; 2011 Dermatology; pp1289-90

2. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus and scleromyxedema. J Am Acad Dermatol 2001;44:273-81

3. Serdar ZA, Yaser SP, Erfan GT, Gunnes P. Generalised papular sclerodermoid eruption: scleromyxedema. Indian J Dermatol Venerol Leprol 2010;76:592-2

4. Mehta V, Balchandran C, Raghavendra R, Arndt Gottron. Scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol 2009;54:193-5

5. Fesel AM, Donato ML, Duvic M. Complete remission of scleromyxoedema following autologuous stem cell transplantation.Arch Dermatol 2001;137:1071

6. Cokonis Georgakis CD, Falasca G ,Georgikis A, Hegmann WR. Scleromyxedema. Clin Dermatol 2006;24:493

7. Davies F, Baz R. Lenalidomide mode of action:linking bench and clinical finding. Blood Rev 2010;24(Suppl 1):513-9

8. Canueto J, Labrador J, Roman C, Santos-Briz A, Contreras T, Gutierrez NC, et al. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxoedema: a rare disease with new clinical insights. Eur J Haematol 2012;88:450-454

9. Dinnen AM ,Dicken CH. Scleromyxoedema. J Am Acad Dermatol 1995;33:37-43

10. Saigoh S, Tashiro A, Fujita S, Matsui M. Successful treatment of intractable scleromyxoedema with cyclosporine A. Dematology 2003;207:410-411

11. Westheim AI, Lookingbill DP. Plasmapheresis in a patient with scleromyxoedema. Arch Dermatol1987;123:786-789.